COMPANY

Schrodinger

HQ: New York, NY source · schrodinger.com ↗ · New England

Location: New York, NY · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Mature B-Cell Neoplasm Non Hodgkin Lymphoma DLBCL Waldenstrom Macroglobulinemia MALT Lymphoma Follicular Lymphoma Pediatric-Type Follicular Lymphoma IRF4 Gene Rearrangement Nos EBV-Positive DLBCL Burkitt Lymphoma Plasmablastic Lymphoma High-grade B-cell Lymphoma Primary Cutaneous Follicle Center Lymphoma Primary Effusion Lymphoma Mantle Cell Lymphoma DLBCL Germinal Center B-Cell Type Primary Mediastinal Large B Cell Lymphoma T-Cell/Histiocyte Rich Lymphoma ALK-Positive Large B-Cell Lymphoma Primary Cutaneous Diffuse Large B-Cell Lymphoma Splenic Marginal Zone Lymphoma Chronic Lymphocytic Leukemia Nodal Marginal Zone Lymphoma Nos HHV8-Positive DLBCL Lymphoplasmacytic Lymphoma Duodenal-Type Follicular Lymphoma Acute Myeloid Leukemia High-Risk and Very High-Risk Myelodysplastic Syndromes SGR-1505 SGR-2921 SGR-3515

3Trials (company is sponsor)15NIH grants

Timeline

Jun 18, 2024 Trial start Phase 1: Study of SGR-3515 In Participants With Advanced Solid Tumors. source ↗
Sep 27, 2023 Trial start Phase 1: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome source ↗
Apr 10, 2023 Trial start Phase 1: Study of SGR-1505 in Mature B-Cell Neoplasms source ↗

Upcoming milestones

Oct 31, 2026 (ESTIMATED) · Phase 1 · Study of SGR-3515 In Participants With Advanced Solid Tumors. · NCT06463340
2027-11 (ESTIMATED) · Phase 1 · Study of SGR-1505 in Mature B-Cell Neoplasms · NCT05544019

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05544019	Study of SGR-1505 in Mature B-Cell Neoplasms	Phase 1	Recruiting	Apr 10, 2023	2027-11 (estimated)
NCT05961839	Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Phase 1	Terminated	Sep 27, 2023	Aug 14, 2025 (actual)
NCT06463340	Study of SGR-3515 In Participants With Advanced Solid Tumors.	Phase 1	Recruiting	Jun 18, 2024	Oct 31, 2026 (estimated)

NIH awards 15

Annual award amounts. Total $3.7M.

Aug 31, 2012 NIH award 5R44GM080726-05 FY2012: $295,779 awarded for that fiscal year; activity R44 (SBIR); PI FARID, RAMY; recipient as written: SCHRODINGER, INC., PORTLAND, OR. Commercial Software for Modeling of G Protein-Coupl source ↗
Aug 30, 2011 NIH award 5R44GM080726-04 FY2011: $389,097 awarded for that fiscal year; activity R44 (SBIR); PI FARID, RAMY; recipient as written: SCHRODINGER, INC., PORTLAND, OR. Commercial Software for Modeling of G Protein-Coupl source ↗
Sep 3, 2010 NIH award 2R44GM080726-03 FY2010: $374,255 awarded for that fiscal year; activity R44 (SBIR); PI FARID, RAMY; recipient as written: SCHRODINGER, INC., PORTLAND, OR. Commercial Software for Modeling of G Protein-Coupl source ↗
Mar 25, 2009 NIH award 5R43GM080726-02 FY2009: $150,482 awarded for that fiscal year; activity R43 (SBIR); PI FARID, RAMY; recipient as written: SCHRODINGER, INC., PORTLAND, OR. Commercial Software for Modeling of G Protein-Coupl source ↗
Apr 7, 2008 NIH award 1R43GM080726-01A1 FY2008: $150,361 awarded for that fiscal year; activity R43 (SBIR); PI FARID, RAMY; recipient as written: SCHRODINGER, INC., PORTLAND, OR. Commercial Software for Modeling of G Protein-Cou source ↗
2003 NIH award 1R43GM067312-01 FY2003: $99,987 awarded for that fiscal year; activity R43 (SBIR); PI MURPHY, ROBERT B; recipient as written: SCHRODINGER, INC., PORTLAND, OR. Modeling Metal-Containing Biological Systems source ↗
Jun 22, 2000 NIH award 5R44GM053301-03 FY2000: $351,348 awarded for that fiscal year; activity R44 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, OR. POLARIZABLE FORCE FIELDS FOR PEPTIDES AND PROT source ↗
Mar 15, 1999 NIH award 2R44GM053301-02A1 FY1999: $374,999 awarded for that fiscal year; activity R44 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, OR. POLARIZABLE FORCE FIELDS FOR PEPTIDES AND PR source ↗
Feb 28, 1997 NIH award 5R44GM051740-03 FY1997: $374,977 awarded for that fiscal year; activity R44 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, OR. NEW METHODS FOR QUANTUM BIOCHEMISTRY IN SOLUTI source ↗
Apr 17, 1996 NIH award 1R43GM053301-01A1 FY1996: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, OR. POLARIZABLE FORCE FIELDS FOR PEPTIDES AND PR source ↗
Mar 1, 1996 NIH award 2R44GM051740-02 FY1996: $375,000 awarded for that fiscal year; activity R44 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, OR. NEW METHODS FOR QUANTUM BIOCHEMISTRY IN SOLUTI source ↗
Aug 31, 1994 NIH award 1R43GM051740-01 FY1994: $79,750 awarded for that fiscal year; activity R43 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, OR. NEW METHODS FOR QUANTUM BIOCHEMISTRY IN SOLUTIO source ↗
Aug 31, 1994 NIH award 5R44GM046160-03 FY1994: $250,000 awarded for that fiscal year; activity R44 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, OR. PSEUDOSPECTRAL METHODS FOR QUANTUM BIOCHEMISTR source ↗
Aug 24, 1993 NIH award 2R44GM046160-02 FY1993: $250,000 awarded for that fiscal year; activity R44 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, OR. PSEUDOSPECTRAL METHODS FOR QUANTUM BIOCHEMISTR source ↗
Mar 13, 1991 NIH award 1R43GM046160-01 FY1991: $50,000 awarded for that fiscal year; activity R43 (SBIR); PI RINGNALDA, MURCO; recipient as written: SCHRODINGER, INC., PORTLAND, CA. PSEUDOSPECTRAL METHODS FOR QUANTUM BIOCHEMISTRY source ↗